AstraZeneca COVID-19 Vaccine Gets UK Nod For Emergency Use
Portfolio Pulse from Mohit Manghnani
AstraZeneca's COVID-19 vaccine, co-developed with Oxford University, received emergency use approval in the UK. The vaccine, showing 70-90% efficacy, is the second approved in the UK after Pfizer/BioNTech's. The UK has ordered 100 million doses, enough for 50 million people.
December 30, 2020 | 8:03 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioNTech, in partnership with Pfizer, was the first to have a COVID-19 vaccine approved in the UK. AstraZeneca's approval introduces competition but supports the vaccination effort.
AstraZeneca's approval adds competition but also supports the overall vaccination effort, likely resulting in a neutral short-term impact on BioNTech's stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
NEUTRAL IMPACT
Pfizer's COVID-19 vaccine was the first to receive UK approval. AstraZeneca's approval adds competition but also supports the overall vaccination effort.
While AstraZeneca's approval introduces competition, it also complements Pfizer's efforts in the UK's vaccination campaign. The impact on Pfizer's stock is likely neutral in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
AstraZeneca's COVID-19 vaccine received UK emergency use approval, boosting its role in the UK's immunization efforts. The UK has ordered 100 million doses, enhancing AstraZeneca's market position.
The approval of AstraZeneca's vaccine in the UK and the large order of 100 million doses are significant positive developments for the company, likely boosting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100